These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 39153202)

  • 1. Cobb syndrome effectively treated with trametinib.
    Sun Y; Yang X; Fan X; Su L; Cai R
    Ann Clin Transl Neurol; 2024 Oct; 11(10):2811-2814. PubMed ID: 39153202
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Co-treatment with panitumumab and trastuzumab augments response to the MEK inhibitor trametinib in a patient-derived xenograft model of pancreatic cancer.
    Lindberg JM; Newhook TE; Adair SJ; Walters DM; Kim AJ; Stelow EB; Parsons JT; Bauer TW
    Neoplasia; 2014 Jul; 16(7):562-71. PubMed ID: 25117978
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhancing Therapeutic Efficacy of Oncolytic Herpes Simplex Virus with MEK Inhibitor Trametinib in Some BRAF or KRAS-Mutated Colorectal or Lung Carcinoma Models.
    Zhou X; Zhao J; Zhang JV; Wu Y; Wang L; Chen X; Ji D; Zhou GG
    Viruses; 2021 Sep; 13(9):. PubMed ID: 34578339
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Monitoring Arteriovenous Malformation Response to Genotype-Targeted Therapy.
    Edwards EA; Phelps AS; Cooke D; Frieden IJ; Zapala MA; Fullerton HJ; Shimano KA
    Pediatrics; 2020 Sep; 146(3):. PubMed ID: 32859736
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trametinib overcomes KRAS-G12V-induced osimertinib resistance in a leptomeningeal carcinomatosis model of EGFR-mutant lung cancer.
    Fukuda K; Otani S; Takeuchi S; Arai S; Nanjo S; Tanimoto A; Nishiyama A; Naoki K; Yano S
    Cancer Sci; 2021 Sep; 112(9):3784-3795. PubMed ID: 34145930
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Topical trametinib for epidermal and sebaceous nevi in a child with Schimmelpenning-Feuerstein-Mims syndrome.
    Haller CN; Leszczynska MA; Brichta L; Maier E; Riddington IM; Choate KA; Levy ML
    Pediatr Dermatol; 2024; 41(3):523-525. PubMed ID: 38273779
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The HSP90 inhibitor, NVP-AUY922, sensitizes KRAS-mutant non-small cell lung cancer with intrinsic resistance to MEK inhibitor, trametinib.
    Park KS; Oh B; Lee MH; Nam KY; Jin HR; Yang H; Choi J; Kim SW; Lee DH
    Cancer Lett; 2016 Mar; 372(1):75-81. PubMed ID: 26723875
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MEK inhibitor trametinib does not prevent the growth of anaplastic lymphoma kinase (ALK)-addicted neuroblastomas.
    Umapathy G; Guan J; Gustafsson DE; Javanmardi N; Cervantes-Madrid D; Djos A; Martinsson T; Palmer RH; Hallberg B
    Sci Signal; 2017 Nov; 10(507):. PubMed ID: 29184034
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dasatinib sensitises KRAS-mutant cancer cells to mitogen-activated protein kinase kinase inhibitor via inhibition of TAZ activity.
    Rao G; Kim IK; Conforti F; Liu J; Zhang YW; Giaccone G
    Eur J Cancer; 2018 Aug; 99():37-48. PubMed ID: 29902613
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Zoledronic acid enhances the efficacy of the MEK inhibitor trametinib in KRAS mutant cancers.
    Dai X; Xia H; Zhou S; Tang Q; Bi F
    Cancer Lett; 2019 Feb; 442():202-212. PubMed ID: 30429107
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I study of the MEK inhibitor trametinib in combination with the AKT inhibitor afuresertib in patients with solid tumors and multiple myeloma.
    Tolcher AW; Patnaik A; Papadopoulos KP; Rasco DW; Becerra CR; Allred AJ; Orford K; Aktan G; Ferron-Brady G; Ibrahim N; Gauvin J; Motwani M; Cornfeld M
    Cancer Chemother Pharmacol; 2015 Jan; 75(1):183-9. PubMed ID: 25417902
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic potential of trametinib to inhibit the mutagenesis by inactivating the protein kinase pathway in non-small cell lung cancer.
    Jeanson A; Boyer A; Greillier L; Tomasini P; Barlesi F
    Expert Rev Anticancer Ther; 2019 Jan; 19(1):11-17. PubMed ID: 30513023
    [No Abstract]   [Full Text] [Related]  

  • 13. Early response in phosphorylation of ribosomal protein S6 is associated with sensitivity to trametinib in colorectal cancer cells.
    Hirashita Y; Tsukamoto Y; Kudo Y; Kakisako D; Kurogi S; Hijiya N; Nakada C; Uchida T; Hirashita T; Hiratsuka T; Akagi T; Ueda Y; Shiroshita H; Etoh T; Mizukami K; Honda K; Okimoto T; Kodama M; Inomata M; Moriyama M; Murakami K
    Lab Invest; 2021 Aug; 101(8):1036-1047. PubMed ID: 33911189
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trametinib radiosensitises RAS- and BRAF-mutated melanoma by perturbing cell cycle and inducing senescence.
    Schick U; Kyula J; Barker H; Patel R; Zaidi S; Gregory C; Hafsi H; Roulstone V; Deutsch E; McLaughlin M; Harrington K
    Radiother Oncol; 2015 Nov; 117(2):364-75. PubMed ID: 26163092
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-PD-1 in Combination With Trametinib Suppresses Tumor Growth and Improves Survival of Intrahepatic Cholangiocarcinoma in Mice.
    Wabitsch S; Tandon M; Ruf B; Zhang Q; McCallen JD; McVey JC; Ma C; Green BL; Diggs LP; Heinrich B; Greten TF
    Cell Mol Gastroenterol Hepatol; 2021; 12(3):1166-1178. PubMed ID: 34033968
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Trametinib (GSK1120212).
    Zeiser R; Andrlová H; Meiss F
    Recent Results Cancer Res; 2018; 211():91-100. PubMed ID: 30069762
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cobimetinib and trametinib inhibit platelet MEK but do not cause platelet dysfunction.
    Unsworth AJ; Bye AP; Kriek N; Sage T; Osborne AA; Donaghy D; Gibbins JM
    Platelets; 2019; 30(6):762-772. PubMed ID: 30252580
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of MEK suppresses hepatocellular carcinoma growth through independent MYC and BIM regulation.
    Zhou X; Zhu A; Gu X; Xie G
    Cell Oncol (Dordr); 2019 Jun; 42(3):369-380. PubMed ID: 30788663
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antitumor activity of the MEK inhibitor trametinib on intestinal polyp formation in Apc(Δ716) mice involves stromal COX-2.
    Fujishita T; Kajino-Sakamoto R; Kojima Y; Taketo MM; Aoki M
    Cancer Sci; 2015 Jun; 106(6):692-699. PubMed ID: 25855137
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lung Adenocarcinoma With Primary LIMD1-BRAF Fusion Treated With MEK Inhibitor: A Case Report.
    Wang CY; Hsia JY; Li CH; Ho CC; Chao WR; Wu MF
    Clin Lung Cancer; 2021 Nov; 22(6):e878-e880. PubMed ID: 34148767
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.